Related Experiment Video
Updated: Mar 9, 2026
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
Published on: May 23, 2025
ACUTE RETINAL NECROSIS AFTER ADMINISTRATION OF ADALIMUMAB, A SYSTEMIC ANTITUMOR NECROSIS FACTOR ANTIBODY
Sid A Schechet1, Kevin Garff2, Karen Klima1
1Department of Ophthalmology and Visual Sciences, University of Maryland, Baltimore, Maryland.
Purpose:
To report a case of acute retinal necrosis in a patient on anti-tumor necrosis factor α immunosuppressive therapy.
Methods:
Case report.
Results:
A 47-year-old man with psoriasis presented with blurred vision and floaters in the left eye 4 days after receiving his fourth dose of adalimumab, a tumor necrosis factor α antagonist. He was diagnosed with acute retinal necrosis and was treated with intravenous acyclovir as well as prophylactic laser barricade. Seven years later, he is 20/20 with no history of a retinal detachment.
Conclusion:
Physicians prescribing tumor necrosis factor α antagonist immunosuppressive therapy should be aware of the potential of developing acute retinal necrosis.
